<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119013</url>
  </required_header>
  <id_info>
    <org_study_id>ADPKD-heart</org_study_id>
    <nct_id>NCT02119013</nct_id>
  </id_info>
  <brief_title>Effects of Somatostatin on ADPKD Heart</brief_title>
  <official_title>EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A MATCHED-COHORT, SPECKLE-TRACKING ECHOCARDIOGRAPHIC STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset
      hypertension and left ventricular (LV) hypertrophy. Since LV hypertrophy is associated with
      LV diastolic function impairment, we aimed to assess the changes over time of LV diastolic
      function in ADPKD patients and whether they were affected by the treatment with the
      somatostatin analogue, octreotide.

      35 ADPKD patients (14 males) aged 34±8 years (mean glomerular filtration rate 82±26
      mL/min/1.73m2) were randomly assigned to 36 month treatment with placebo (n=18) or octreotide
      (n=17). Clinical and echocardiography parameters were evaluated at baseline and study end. LV
      mass (M) and ejection fraction (EF) were calculated according to Devereux formula and biplane
      Simpson's algorithm, respectively. LV filling was assessed by mitral and pulmonary vein flow
      velocity curves and mitral annulus early diastolic velocity peak (Ea) by tissue Doppler
      imaging.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFFECT ON LEFT VENTRICULAR DYASTOLIC FUNCTION</measure>
    <time_frame>3 years</time_frame>
    <description>To assess the changes over time of left ventricular dyastolic function in ADPKD patients and whether they were affected by the treatment with the somatostatin analogue, octreotide</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <condition>Glomerular Filtration Rate &gt; 40 ml/Min</condition>
  <arm_group>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octeotride, 20 mg monthly intramuscular injection for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (salin soluction), intramuscular injection monthly for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octeotride</intervention_name>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of autosomal dominant polycystic kidney disease

          -  glomerular filtration rate grater than 40 ml/min

        Exclusion Criteria:

          -  diabetes mellitus

          -  proteinuria greater than 1 g/24 hours

          -  significant glomerular disease

          -  urinary tract lithiasis and infections

          -  symptomatic gallstones

          -  biliary sludge

          -  cancer

          -  pregnant women

          -  lactanting women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>eleonora riccio, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Eleonora Riccio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

